Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
SAN FRANCISCO, Nov. 08, 2016 -- Hagens Berman Sobol Shapiro LLP reminds investors in Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI) of the securities class action lawsuit and November 21, 2016 Lead Plaintiff deadline.
If you purchased or otherwise acquired securities of SPPI between February 28, 2013 and September 16, 2016 and suffered over $50,000 in losses contact Hagens Berman Sobol Shapiro LLP. For more information visit:
https://www.hbsslaw.com/cases/SPPI
or contact Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000 or emailing [email protected].
During Spectrum’s December 2012 meeting with the U.S. Food and Drug Administration, the FDA noted that one of Spectrum’s drugs, apaziquone, “did not meet the pre-specified criteria for superiority when compared to placebo” and discouraged submission of a New Drug Application.
Three years later, Spectrum submitted a New Drug Application based on similar studies provided to the FDA three years prior. Management repeatedly discussed apaziquone’s status during earnings conference calls but omitted information regarding the FDA’s prior discouragement. On September 14, 2016, the Company announced the FDA’s panel of outside experts found apaziquone had “not shown substantial evidence of a treatment effect over placebo,” sending Spectrum shares down 8% to close at $5.04 that day.
When TheStreet later reported “Spectrum joins an unacceptably long list of drug and biotech companies hurting investors by failing to be fully transparent about their communications with the FDA,” Spectrum shares fell another 2.6%.
“We are investigating the key details of apaziquone and the Company’s dealings with the FDA that Defendants apparently omitted,” said Hagens Berman partner Reed Kathrein.
Whistleblowers: Persons with non-public information regarding Spectrum Pharmaceuticals should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new SEC whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email [email protected].
About Hagens Berman
Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with offices in 10 cities. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the Firm and its successes can be found at www.hbsslaw.com. Read the Firm’s Securities Newsletter, and visit the blog. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.
Contact: Reed Kathrein, 510-725-3000
